The DOI matches its Crossref record; 211 of the 212 references it cites were found in a registry or an index; 81 of the 214 sources its claims cite were checked for support.
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Open accessAbstract
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo- and hypertriglyceridaemic states and their relation to risk of ASCVD, (ii) a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, (iii) the pleiotropic proatherogenic actions of TRL and remnants at the arterial wall, (iv) challenges in defining, quantitating, and assessing the atherogenic properties of remnant particles, and (v) exploration of the relative atherogenicity of TRL and remnants compared to LDL. Assessment of these issues provides a foundation for evaluating approaches to effectively reduce levels of TRL and remnants by targeting either production, lipolysis, or hepatic clearance, or a combination of these mechanisms. This consensus statement updates current understanding in an integrated manner, thereby providing a platform for new therapeutic paradigms targeting TRL and their remnants, with the aim of reducing the risk of ASCVD.
Overview
CoChat Summary
TL;DR
This European Atherosclerosis Society consensus statement appraises evidence that triglyceride-rich lipoproteins (TRL) and their remnants are causally related to atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischaemic stroke, and aortic valve stenosis, and contribute to residual risk on optimized LDL-lowering therapy. It reviews TRL metabolism, remnant atherogenicity, measurement challenges, and emerging therapeutic strategies targeting production, lipolysis, or hepatic clearance.
Key findings
- Epidemiologic and genetic evidence supports a causal relationship between elevated plasma TG, TRL, and TRL remnants and ASCVD risk; the absolute risk increase is greatest for myocardial infarction (approximately four-fold at TG >5 mmol/L or >440 mg/dL vs. <1 mmol/L or <88 mg/dL), and less for ischaemic stroke and aortic stenosis.
- TRL and remnants accumulate at fasting TG levels >1.2 mmol/L (>100 mg/dL); ASCVD risk is considered clinically relevant at fasting TG >1.7 mmol/L (>150 mg/dL), while TG >10 mmol/L (>880 mg/dL) confers high pancreatitis risk.
- Cholesterol-rich remnant particles can contain up to four-fold more cholesterol molecules than LDL (up to 10,000 vs. 2,000–2,700 cholesterol molecules per particle), are enriched in apoE and apoCIII, and are more potent inducers of macrophage foam cells than LDL on a per-particle basis.
- Therapeutic approaches include inhibiting lipoprotein production, reducing cholesteryl ester enrichment of remnants, stimulating lipolysis, and enhancing remnant clearance; however, no definitive measure captures the independent atherogenic potential of TRL and remnants, and randomized controlled trial evidence that lowering TG/TRL reduces ASCVD risk is limited.
Methods
- Consensus statement from a European Atherosclerosis Society Consensus Panel that met in London in January 2020 to critically appraise evidence on TRL and remnant definition, aetiology, metabolism, role in ASCVD, and clinical management.
- References (English language only) were identified through PubMed searches for articles published from 2000 using terms including “triglycerides,” “lipoprotein remnants,” “triglyceride-rich lipoproteins,” “cardiovascular disease,” “atherosclerosis,” “residual risk,” and “therapeutics,” plus reference-list searches.
- The paper is a narrative expert synthesis of epidemiologic, genetic, preclinical, and clinical trial evidence, not a systematic review or meta-analysis.
Limitations
- The paper states that there is no definitive measure capturing the independent atherogenic potential, structural and metabolic variability, or postprandial changes of TRL and remnants; defining remnants is difficult, and proposed TG cut-points are arbitrary though considered clinically useful.
- The paper states that there are no treatment goals for plasma TG or remnant abundance given limited randomized controlled trial evidence that lowering TG or TRL reduces ASCVD risk, and that determining the relative atherogenicity of TRL/remnants vs. LDL will require specific assays.
- Evident from the text: the search strategy was limited to English-language PubMed articles from 2000 onward plus reference lists, and the conclusions are consensus-based expert opinion rather than systematic quantitative synthesis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
33 Valid · 11 Not valid · 56 Not checked · 51 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis.”
§ Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society > Abstract
What the sources say
- Partly supportedcites [1] Austin, 1991, Plasma triglyceride and coronary heart disease, Arterioscler Thromb sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [2] Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [17] Nordestgaard, 2016, Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology, Circ Res sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Disputedcites [19] Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Partly supportedcites [20] Mach, 2020, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked yetcites [24] Austin, 1998, Hypertriglyceridemia as a cardiovascular risk factor, Am J Cardiol source
- Not checked yetcites [25] Nordestgaard, 2014, Triglycerides and cardiovascular disease, Lancet source
- Partly supportedcites [26] Ference, 2019, Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease, JAMA sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked yetcites [27] Varbo, 2019, Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population, Ann Neurol source
- Not checked yetcites [28] Kaltoft, 2020, Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study, Eur Heart J source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Over the past three decades, epidemiologic and genetic evidence has accumulated to support the concept that elevated levels of plasma TG, TRL, and TRL remnants are causally related to an increased risk of ASCVD-related events—myocardial infarction (MI), stroke, and aortic valve stenosis—and all-cause mortality.1,2,17,19,20,24–28”
- Also stated in: § Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance · plain
“Accumulating evidence from epidemiologic and genetic studies is consistent with a causal relationship between ASCVD risk and elevated plasma levels of TG, TRL, and TRL remnants.”
§ Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society > Search strategy > Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance
What the sources say
- Partly supportedcites [1] Austin, 1991, Plasma triglyceride and coronary heart disease, Arterioscler Thromb sourceExperimental — accuracy not yet measured
The Summary (pp. 10–11) reports an epidemiologic association between plasma triglycerides and coronary heart disease and discusses possible genetic susceptibility, including a trait associated with myocardial infarction risk. It also says the findings are not fully consistent and does not establish a causal relationship. The cited passages do not support the broader claims about triglyceride-rich lipoprotein remnants, stroke, aortic valve stenosis, or all-cause mortality. (LLM, conf=0.88)
- Partly supportedcites [2] Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J sourceExperimental — accuracy not yet measured
The Epidemiology section reports associations of markedly elevated triglycerides with myocardial infarction, ischaemic stroke, and total mortality, but notes that the stroke association disappeared after adjustment for other lipid factors. The Genetic studies section says an APOA5 analysis suggests a causal association between triglyceride-mediated pathways and coronary heart disease, while cautioning that genetic studies do not provide clear insights overall. The paper does not establish the claimed causal relationship for all listed outcomes or address aortic valve stenosis. (LLM, conf=0.88)
- Partly supportedcites [17] Nordestgaard, 2016, Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology, Circ Res sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Disputedcites [19] Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA sourceExperimental — accuracy not yet measured
The Results > Triglyceride section reports an initial association with coronary heart disease, but it becomes essentially null after adjustment for HDL-C and non-HDL-C; adjusted associations with stroke are also near null. This conflicts with attributing increased cardiovascular risk from elevated triglycerides to this paper as a causal conclusion. The paper does not assess triglyceride-rich remnants, aortic valve stenosis, or all-cause mortality in the cited findings. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [20] Mach, 2020, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J sourceExperimental — accuracy not yet measured
Section 5.3.2 (page not provided) links triglyceride-rich lipoproteins and their remnants to ASCVD risk, but says their causal effect depends on ApoB-containing particle concentration rather than triglyceride content itself; it also cautions that the genetic evidence for triglycerides is difficult to interpret. The cited passages do not establish the claimed links to all-cause mortality or aortic valve stenosis. Section 9.7.3 instead associates aortic valve stenosis with LDL-C and lipoprotein(a). (LLM, conf=0.88)
- Not checked yetcites [24] Austin, 1998, Hypertriglyceridemia as a cardiovascular risk factor, Am J Cardiol source
- Not checked yetcites [25] Nordestgaard, 2014, Triglycerides and cardiovascular disease, Lancet source
- Partly supportedcites [26] Ference, 2019, Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease, JAMA sourceExperimental — accuracy not yet measured
The Discussion says triglyceride-rich remnant particles appear causally associated with cardiovascular disease risk, and Study Outcomes defines the measured coronary heart disease outcome to include myocardial infarction. The paper does not establish the claimed links to stroke, aortic valve stenosis, or all-cause mortality; its findings also focus on ApoB-containing particle concentration rather than triglyceride levels alone. The indexed passages provide section labels but no page numbers. (LLM, conf=0.88)
- Not checked yetcites [27] Varbo, 2019, Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population, Ann Neurol source
- Not checked yetcites [28] Kaltoft, 2020, Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study, Eur Heart J source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In most people, remnant lipoproteins (and TRL in general) are highly heterogeneous (Figure 1).3,6–9”
§ Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society > Search strategy > Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance
What the sources say
- Supportedcites [3] Björnson, 2019, Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics, J Intern Med source
The Introduction (page unavailable) says TRLs comprise distinct fractions and that newly secreted particles and their remnants occur across the entire size and density range. The Discussion (page unavailable) reports apoB48-containing particles from chylomicrons through VLDL1 and VLDL2, with differing metabolic characteristics, and describes this as part of normal physiology. This supports the broad statement about heterogeneity, though the paper does not quantify the proportion of people. (LLM, conf=0.87)
- Not checked yetcites [6] Gotto, 1986, Introduction to the plasma lipoproteins, Methods Enzymol source
- Not checked yetcites [7] Havel, 1997
- Not checked yetcites [8] Musliner, 1986, Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects, Arteriosclerosis source
- Not checked yetcites [9] McNamara, 1996, Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B, J Lipid Res source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“it is less widely appreciated that fasting levels from as low as ∼1.2 mmol/L (∼100 mg/dL) can be associated with a cluster of metabolic abnormalities that include accumulation of TRL and remnants,14 as well as increased cardiovascular disease events15,16 (Figure 1).”
§ Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society > Search strategy > Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance
What the sources say
- Partly supportedcites [14] Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk, Circulation sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [15] Miller, 1998, Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [16] Lawler, 2020, Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies, Eur Heart J sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
§ Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society > Search strategy > Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance
What the sources say
- Partly supportedcites [29] Do, 2015, Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction, Nature sourceExperimental — accuracy not yet measured
The Results passage labeled Abstract (page not provided) reports that rare APOA5 mutation carriers had a 2.2-fold higher MI/CAD risk, and the discussion there links APOA5, APOC3, and lipoprotein lipase variation to MI risk. This paper reports exome-sequencing association analyses, not a Mendelian randomization study, and the cited passages do not address ANGPTL3, ANGPTL4, or ANGPTL8. (LLM, conf=0.86)
- Supportedcites [30] Jørgensen, 2014, Loss-of-function mutations in APOC3 and risk of ischemic vascular disease, N Engl J Med source
The cited paper supports the apoCIII portion of this multi-citation sentence. Its Abstract (page not provided) reports that APOC3 loss-of-function mutations were associated with lower triglyceride levels and reduced ischemic cardiovascular disease risk; the other genes are not attributed to this source individually. (LLM, conf=0.91)
- Supportedcites [31] Khera, 2017, Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease, JAMA source
This source supports the lipoprotein lipase (LPL) portion of the sentence, which cites several studies for different genes. Its Methods (Statistical Analysis; page not indicated) describe an analysis using common LPL variants and a method equivalent to a cited Mendelian-randomization approach; the Discussion reports an association between those variants and coronary artery disease. It does not need to cover every gene listed alongside LPL. (LLM, conf=0.90)
- Partly supportedcites [32] Stitziel, 2017, ANGPTL3 deficiency and protection against coronary artery disease, J Am Coll Cardiol sourceExperimental — accuracy not yet measured
The Discussion (page not provided) places the paper’s ANGPTL3 findings alongside genetic evidence concerning APOA5, APOC3, ANGPTL4, and lipoprotein lipase activity. Our copy does not address ANGPTL8 or characterize the full set of studies as Mendelian randomization studies, so it supports only part of the attributed list. (LLM, conf=0.86)
- Supportedcites [33] Dewey, 2016, Inactivating variants in ANGPTL4 and risk of coronary artery disease, N Engl J Med source
The Methods and Results report a study of ANGPTL4 variants, triglyceride levels, and coronary artery disease risk. This paper supports the ANGPTL4 example within the citing sentence’s group of genetic studies; the other genes are not being attributed to this citation alone. (LLM, conf=0.88)
- Supportedcites [34] Stitziel, 2016, Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease, N Engl J Med source
The paper’s ANGPTL4 results and its section on coding variation in LPL report associations between variants in those genes and coronary artery disease. As one citation in a group, it supports the sentence’s reference to informative genetic-variant studies of ANGPTL4 and LPL. (LLM, conf=0.88)
- Partly supportedcites [35] Helkkula, 2021, ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease, PLoS Genet sourceExperimental — accuracy not yet measured
The Results (Primary analyses; page unavailable) examine ANGPTL8 and ANGPTL4 protein-truncating variants and their associations with lipid levels, so this paper fits the sentence’s broader point about informative genetic studies. But the Discussion (page unavailable) explicitly calls the study observational and says it cannot directly reveal causal effects; the copy does not support identifying this particular study as Mendelian randomization. (LLM, conf=0.86)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
66 more claims · 15 with their cited sources checked
Create a free account to see all 151 claims and to verify the 133 references still open.
- It may state two separate claims as one. 70
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The data from the PROMINENT trial are consistent with increased efficiency in conversion of triglyceride-rich lipoprotein remnants to LDL rather than their removal by the liver. 21”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [21]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“yet highly effective therapies for reducing triglyceride levels are lacking. 5”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypertriglyceridemia is frequently identified in clinical practice, yet effective therapies are lacking. 5,17,18”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Though LDL is widely recognized as the dominant atherogenic factor, 149 the current analysis suggested that LDL‐C, a surrogate of LDL particle concentration, did not appear to be targeted by EPA and DHA in the treatment of dyslipidemia, an outcome in agreement with many published meta‐analysis results. 4 , 17 , 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result of this process, CM are converted into chylomicron remnants, whereas VLDL particles are gradually transformed into intermediate-density lipoproteins (IDL) and, in part, into low-density lipoproteins (LDL) through further delipidation catalyzed by hepatic lipase [11].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [11]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society > Search strategy > Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance
“Remnant lipoproteins are enriched in cholesterol (both free and esterified) and are depleted in apoC proteins and enriched in apoE (Figure 2).”
§ Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society > Role of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease > How do triglyceride-rich lipoproteins and remnants exert atherogenic effects at the arterial wall?
“The proteome of remnant particles is enriched in apoE and apoCIII”
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 2×
“66,153,154 Estimation of VLDL cholesterol concentration by nuclear magnetic resonance (NMR) spectroscopy analysis was recently proposed as a surrogate for remnant lipoproteins.”
BackgroundMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · cited 3×
“13,20 Non-fasting TG is equivalent, if not superior, to fasting TG in assessing potential ASCVD risk.”
BackgroundSelf-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962 · cited 1×
“17,25,93,104,206”
Self-citationBrown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 1×
“ASCVD risk, although it was suggested that only a modest part of this benefit was due to changes in TRL levels.(176) The lack of benefit in”
Background
Cited by
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Qiu, S., Cai, Y., Yao, H., Lin, C., Xie, Y., Tang, S., & Zhang, A. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01399-3 · Cited by 884
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Self-citationThe Role of Inflammation in Cardiovascular Disease
Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112906 · Cited by 724
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Self-citationOkamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Metadata
- Authors
- Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M.-R., Tokgözoğlu, L. S., Tybjaerg-Hansen, A., Stock, J. K., & Catapano, A. L.
- Affiliations
- Columbia University (US)
- University of Glasgow (GB)
- Inserm (FR)
- Sahlgrenska University Hospital (SE)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University of Palermo (IT)
- University of Cambridge (GB)
- Université de Montréal (CA)
- Western University (CA)
- Wageningen University & Research (NL)
- University of Toronto (CA)
- Tufts University (US)
- University of Copenhagen (DK)
- National Institutes of Health (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Helsinki (FI)
- Hacettepe University (TR)
- Department of Clinical Biochemistry, Blegdamsvej 9, Rigshospitalet , Copenhagen 2100, Denmark
- European Atherosclerosis Society (SE)
- University of Milan (IT)
- Corresponding author
- Ginsberg, Henry N
- ORCID
- Ginsberg, Henry N
- Packard, Chris J
- Chapman, M John
- Borén, Jan
- Aguilar-Salinas, Carlos A
- Averna, Maurizio
- Gaudet, Daniel
- Hegele, Robert A
- Kersten, Sander
- Lewis, Gary F
- Lichtenstein, Alice H
- Moulin, Philippe
- Nordestgaard, Børge G
- Remaley, Alan T
- Staels, Bart
- Stroes, Erik S G
- Taskinen, Marja-Riitta
- Tokgözoğlu, Lale S
- Catapano, Alberico L
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-09-02
- Volume
- 42
- Issue
- 47
- Pages
- 4791-4806
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC8670783
- OpenAlex
- W3197326839
- Cited by
- 979
- References
- 212
- Citations by year
- 2026: 253 · 2025: 237 · 2024: 206 · 2023: 164 · 2022: 108 · 2021: 10
- FWCI
- 81.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- Socio-Environmental Systems Modeling (submittedVersion, cc-by-nc)
- HAL (submittedVersion, cc-by-nc)
- Työväentutkimus Vuosikirja (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
- Funders
- The European Atherosclerosis Society Consensus Panel
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- triglyceride-rich lipoproteins, remnant lipoproteins, atherosclerotic cardiovascular disease, hypertriglyceridemia, residual cardiovascular risk, lipolysis, atherogenicity, LDL-C lowering therapy, therapeutic target, myocardial infarction, ischemic stroke, aortic stenosis
- MeSH terms
- Cardiovascular Diseases, Brain Ischemia, Humans, Lipoproteins, Triglycerides, Stroke, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. https://app.cochat.ai/papers/10.1093/eurheartj/ehab551
- The paper
- Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M.-R., Tokgözoğlu, L. S., . . . Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.